Company Filing History:
3 out of 27 
1 out of 119 
Years Active: 2013-2018
Title: **Leonie Young: Innovator in Breast Cancer Diagnostics**
Introduction
Leonie Young is a notable inventor based in Dublin, IE, who has made significant contributions to the field of medical diagnostics, particularly in breast cancer. With a total of three patents to her name, her work focuses on innovative approaches to identify and treat metastatic breast cancer, promising to enhance outcomes for patients facing this challenging disease.
Latest Patents
Among her latest patents is the groundbreaking work on ADAM22, which is utilized as a prognostic variable and therapeutic target for metastatic breast cancer. This invention describes a method for diagnosing the metastatic potential of breast cancer by assaying tumor samples for the expression of A Disintegrin and Metalloproteinase 22 (ADAM22). The presence of ADAM22 is correlated with a higher likelihood of metastasis compared to ADAM22 negative patients. Furthermore, the patent outlines a treatment involving agents such as leucine-rich glioma-inactivated protein 1 (LGI1) and LGI1 peptide mimics aimed at inhibiting the migration of endocrine-resistant breast cancer cells.
Career Highlights
Leonie Young's career is marked by her significant roles within esteemed institutions, including the Royal College of Surgeons in Ireland and University College Dublin. These affiliations have allowed her to collaborate on various research projects, ultimately leading to her impactful inventions.
Collaborations
Throughout her career, Leonie has collaborated with notable colleagues such as Damian McCartan and Christopher Byrne. These partnerships have furthered her research endeavors, contributing to the development of innovative methods for breast cancer diagnostics and treatment.
Conclusion
Leonie Young's contributions to the field of breast cancer diagnostics exemplify the vital role that innovative inventions play in healthcare. Her patents not only enhance the understanding of metastatic potential in breast cancer patients but also pave the way for novel therapeutic strategies. As she continues her work, Leonie Young remains a key figure in advancing medical innovation for better patient outcomes.